Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bi Rg 587
2. Bi-rg-587
3. Birg587
4. Hemihydrate, Nevirapine
5. Nevirapine
6. Viramune
1. 220988-26-1
2. B7xf2td73c
3. 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;hydrate
4. Unii-b7xf2td73c
5. Schembl1923903
6. Dtxsid30176606
7. Nevirapine Hemihydrate [usp-rs]
8. Nevirapine Hemihydrate [who-dd]
9. Nevirapine Hemihydrate [who-ip]
10. Nevirapine Hemihydrate [ep Monograph]
11. Nevirapine Hemihydrate [usp Monograph]
12. Nevirapinum Hemihydrate [who-ip Latin]
13. Q27274473
14. 6h-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-, Hydrate (2:1)
Molecular Weight | 550.6 g/mol |
---|---|
Molecular Formula | C30H30N8O3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 2 |
Exact Mass | 550.24408685 g/mol |
Monoisotopic Mass | 550.24408685 g/mol |
Topological Polar Surface Area | 117 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 397 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)
Cytochrome P-450 CYP3A Inducers
Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inducers.)
Reverse Transcriptase Inhibitors
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)
Related Excipient Companies
Excipients by Applications
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A UNII-B7XF2TD73C manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of UNII-B7XF2TD73C, including repackagers and relabelers. The FDA regulates UNII-B7XF2TD73C manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. UNII-B7XF2TD73C API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of UNII-B7XF2TD73C manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A UNII-B7XF2TD73C supplier is an individual or a company that provides UNII-B7XF2TD73C active pharmaceutical ingredient (API) or UNII-B7XF2TD73C finished formulations upon request. The UNII-B7XF2TD73C suppliers may include UNII-B7XF2TD73C API manufacturers, exporters, distributors and traders.
click here to find a list of UNII-B7XF2TD73C suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A UNII-B7XF2TD73C DMF (Drug Master File) is a document detailing the whole manufacturing process of UNII-B7XF2TD73C active pharmaceutical ingredient (API) in detail. Different forms of UNII-B7XF2TD73C DMFs exist exist since differing nations have different regulations, such as UNII-B7XF2TD73C USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A UNII-B7XF2TD73C DMF submitted to regulatory agencies in the US is known as a USDMF. UNII-B7XF2TD73C USDMF includes data on UNII-B7XF2TD73C's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The UNII-B7XF2TD73C USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of UNII-B7XF2TD73C suppliers with USDMF on PharmaCompass.
A UNII-B7XF2TD73C written confirmation (UNII-B7XF2TD73C WC) is an official document issued by a regulatory agency to a UNII-B7XF2TD73C manufacturer, verifying that the manufacturing facility of a UNII-B7XF2TD73C active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting UNII-B7XF2TD73C APIs or UNII-B7XF2TD73C finished pharmaceutical products to another nation, regulatory agencies frequently require a UNII-B7XF2TD73C WC (written confirmation) as part of the regulatory process.
click here to find a list of UNII-B7XF2TD73C suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing UNII-B7XF2TD73C as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for UNII-B7XF2TD73C API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture UNII-B7XF2TD73C as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain UNII-B7XF2TD73C and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a UNII-B7XF2TD73C NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of UNII-B7XF2TD73C suppliers with NDC on PharmaCompass.
UNII-B7XF2TD73C Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of UNII-B7XF2TD73C GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right UNII-B7XF2TD73C GMP manufacturer or UNII-B7XF2TD73C GMP API supplier for your needs.
A UNII-B7XF2TD73C CoA (Certificate of Analysis) is a formal document that attests to UNII-B7XF2TD73C's compliance with UNII-B7XF2TD73C specifications and serves as a tool for batch-level quality control.
UNII-B7XF2TD73C CoA mostly includes findings from lab analyses of a specific batch. For each UNII-B7XF2TD73C CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
UNII-B7XF2TD73C may be tested according to a variety of international standards, such as European Pharmacopoeia (UNII-B7XF2TD73C EP), UNII-B7XF2TD73C JP (Japanese Pharmacopeia) and the US Pharmacopoeia (UNII-B7XF2TD73C USP).
LOOKING FOR A SUPPLIER?